$150 million up front + up to $1.7 billion in milestone payments.
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
Shares in volatile small-cap Agenus (AGEN) leapt on Monday following news that the company had reached a deal with Merck (MRK) to partner in the “discovery and development of therapeutic
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.
| Website: | www.agenusbio.com |
| Email: | investor@agenusbio.com |
| Main Phone: | +1 781 674-4400 |
| Address: | 3 Forbes Road |
| State: | MA |
| City / Town: | Lexington |
| Country: | US |
| Postal Code: | 02421-7305 |
| Exchange: | NSC |
| CEO: | Garo H Armen |
| Employees: | 359 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
$150 million up front + up to $1.7 billion in milestone payments.
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
Shares in volatile small-cap Agenus (AGEN) leapt on Monday following news that the company had reached a deal with Merck (MRK) to partner in the “discovery and development of therapeutic
Shares in small cap biotechnology company Agenus, Inc. (AGEN) saw its stock gap up over 20 percent before the opening bell this morning on news that the malaria vaccine it’s developing
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
